HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Limitation of myocardial infarct size by metabolic interventions that reduce accumulation of fatty acid metabolites in ischemic myocardium.

Abstract
The effects on myocardial damage of metabolic interventions by nicotinic acid, oxfenicine, or a combination of the two were assessed in open-chest dogs exposed to coronary artery occlusion for 6 hours. The accumulation of metabolites of free fatty acids (FFAs) was studied in tissue samples of the left ventricle taken 60 minutes after coronary occlusion in separate animals. The percentage of the hypoperfused zone that evolved to infarction was 96 +/- 3% (mean +/- SEM) in control dogs, 74 +/- 4% in dogs treated with nicotinic acid (p less than 0.05 vs control dogs), 72 +/- 2% in dogs treated with oxfenicine (p less than 0.05 vs control dogs), and 54 +/- 5% in dogs with combined nicotinic acid and oxfenicine (p less than 0.05 vs control dogs, p less than 0.05 vs nicotinic acid and oxfenicine). Arterial FFA concentration was markedly reduced in dogs treated with nicotinic acid and those treated with combination nicotinic acid and oxfenicine. The accumulation of long-chain acyl carnitine was substantially reduced in the ischemic myocardium after nicotinic acid, oxfenicine, and a combination of the two, whereas the lowering of long-chain acyl CoA was less pronounced. Thus, nicotinic acid and oxfenicine, which depress myocardial FFA metabolism by different mechanisms, both reduce myocardial infarct size and their effects are additive.
AuthorsH Vik-Mo, O D Mjøs, J R Neely, P R Maroko, L G Ribeiro
JournalAmerican heart journal (Am Heart J) Vol. 111 Issue 6 Pg. 1048-54 (Jun 1986) ISSN: 0002-8703 [Print] United States
PMID3716978 (Publication Type: Journal Article)
Chemical References
  • Acyl Coenzyme A
  • Adenine Nucleotides
  • Fatty Acids, Nonesterified
  • Lactates
  • Niacin
  • Acetylcarnitine
  • 4-hydroxyphenylglycine
  • Glycine
Topics
  • Acetylcarnitine (analysis)
  • Acyl Coenzyme A (analysis)
  • Adenine Nucleotides (analysis)
  • Animals
  • Dogs
  • Drug Synergism
  • Drug Therapy, Combination
  • Fatty Acids, Nonesterified (metabolism)
  • Female
  • Glycine (administration & dosage, analogs & derivatives, therapeutic use)
  • Lactates (analysis)
  • Male
  • Myocardial Infarction (metabolism)
  • Myocardium (analysis)
  • Niacin (administration & dosage, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: